Steve Elms

Board Director

Director

Marker Therapeutics, Inc.Zosano Pharma CorpMarker Therapeutics, Inc.Adma Biologics, Inc.

Insider activity · 24 months2 buys1 saleCumulative net flow

Nov 24 · 0 buys · 0 salesDec 24 · 1 buy · 0 salesJan 25 · 0 buys · 0 salesFeb 25 · 0 buys · 0 salesMar 25 · 0 buys · 0 salesApr 25 · 0 buys · 0 salesMay 25 · 0 buys · 0 salesJun 25 · 0 buys · 1 saleJul 25 · 0 buys · 0 salesAug 25 · 0 buys · 0 salesSept 25 · 0 buys · 0 salesOct 25 · 0 buys · 0 salesNov 25 · 0 buys · 0 salesDec 25 · 0 buys · 0 salesJan 26 · 0 buys · 0 salesFeb 26 · 0 buys · 0 salesMar 26 · 1 buy · 0 salesApr 26 · 0 buys · 0 salesMay 26 · 0 buys · 0 salesJun 26 · 0 buys · 0 salesJul 26 · 0 buys · 0 salesAug 26 · 0 buys · 0 salesSept 26 · 0 buys · 0 salesOct 26 · 0 buys · 0 sales

Total declarations

Companies

▲ Purchases (2 ops.)

€128k

▼ Sales (4 ops.)

€6.6M

Latest filing published 09 Mar 2026 for Adma Biologics, INC., €94k. Read the official filing

Filing timeline

BuySale

Steve Elms

Insider track record

Disclosed buys

Disclosed sells

T+90 hit rate

T+90 mean return

-49.1%

Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.

Signal history

Steve Elms: trading record in brief

Filings by Steve Elms span 3 companies, the busiest being Adma Biologics, Inc., Marker Therapeutics, Inc. and Zosano Pharma Corp. We count 14 filings; the first trade dates from 8 June 2021 and the latest from 5 March 2026.

Both buying and selling appear: 2 purchases worth €128k, against 4 sales worth €6.6M. Sales outweigh purchases by €6.5M. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Other entries cover 7 share grants and 1 option exercise. 2026 to date brings 1 purchase and no sales.

On 9 March 2026 came the latest disclosure, an open-market purchase for €94k in Adma Biologics, Inc. The median gap between a trade and its publication by SEC (Form 4) is 2 days. US insiders must file a Form 4 within two business days of a trade. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.